Starton Holdings, Inc., (STA)

About Starton Holdings, Inc.,

We are a clinical -stage biotechnology company focused on improving standard -of -care therapies for people with cancer through application of our proprietary platform of delivery technology systems. We use continuous delivery of FDA -approved , active ingredients in an attempt to develop and bring products to market in either new indications or with enhanced outcomes in existing indications.

From Starton Holdings, Inc.,'s Form S-1/A filed with the SEC on 2026-10-28. The issuer's own words — QuantLogix does not paraphrase it.

The offering

Use of proceeds

We currently expect to use the net proceeds from this offering as follows: • approximately $7.3 million to advance Phase 2 clinical development of STAR -LLD -(SC and OCR) in high -risk RRMM; • approximately $6.7 million to fund several IIT studies at certain major academic centers of STAR -LLD-SC in combinations with CAR -T cell therapies and bispecific antibodies in RRMM and lymphoma; • approximately $3.3 million to pay certain outstanding trade payables and amounts due and owing to related parties for goods and services rendered to us.

From Starton Holdings, Inc.,'s Form S-1/A filed with the SEC on 2026-10-28. Quoted from the prospectus.

Financials, as filed

Figures as stated in the prospectus, not QuantLogix estimates. From Starton Holdings, Inc.,'s Form S-1/A filed with the SEC on 2026-10-28.

Risks Starton Holdings, Inc., flags in its own filing

• We are a clinical stage biopharmaceutical company with a limited operating history and no products approved for commercial sale.
• We identified a material weakness in our internal control over financial reporting.
• Even if this offering is successful, we will require substantial additional capital to finance our operations, and failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our development programs or commercialization efforts.
• If we are unable to develop or commercialize our product candidates on a timely or cost -effective basis, including STAR -LLD and future pipeline programs, our operating results will suffer.
• We face intense competition from other development -stage companies and large pharmaceutical companies that could limit or make obsolete our market objectives.
• We depend on our ability to protect our intellectual property and proprietary rights, including in international markets.

The first 6 items of the issuer's “Summary of Risk Factors”, verbatim — the prospectus lists more. From Starton Holdings, Inc.,'s Form S-1/A filed with the SEC on 2026-10-28.

QL Listing Score — the prospectus, scored

From Starton Holdings, Inc.,'s Form S-1/A filed with the SEC on 2026-10-28. Extraction is deterministic — the same filing always produces the same score; 275k characters of the document were scanned. Technology signals are lexical indicators, not a technical audit. Not investment advice; the debut itself will be this score's first grade.